Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Teva Pharmaceutical Industries Ltd. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 7th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Teva Pharmaceutical Industries Ltd ended up being:
Interest coverage, a measure of earnings relative to interest payments, is -4.72 -- which is good for besting only 13.34% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The company's compound free cash flow growth rate over the past 4.74 years comes in at -0.29%; that's greater than merely 5.5% of US stocks we're applying DCF forecasting to.
33% of the company's capital comes from equity, which is greater than just 9.87% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
NVST, SXTC, INFU, LUMO, and OSMT can be thought of as valuation peers to TEVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
) Shield Therapeutics plc ("Shield" or the "Group" or the "Company") Business and trading update London, UK, 15 January 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), provides a business and unaudited trading update for the year ended 31 December 2020. Operational highlights Feraccru® 2020 sales volumes in Europe increased by ~70% year-on-year China IND application submitted First stage of paediatric study plan completed Teva challenge to Shield's European patents withdrawn Shield continues to evaluate options for launching…
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability of a generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women t
Teva Pharmaceutical Industries Limited (TEVA) 39th Annual JP Morgan Healthcare Conference January 12, 2021 10:00 A.M. ET Company Participants Kåre Schultz - President and Chief Executive Officer Eli Kalif - EVP and CFO Conference Call Participants Chris Schott - J.P. Morgan Presentation Chris Schott Good morning, everybody. I'm Chris Schott...
SA Transcripts on Seeking Alpha | January 13, 2021
Parkinson’s Disease Therapeutic Market Report evaluated the historical and current performance of the market, especially highlighting the key trends and growth opportunities. Parkinson’s Disease Therapeutic market report discussed this scenario of market size with reference to volume and share. Parkinson’s
CMI published a business research report on “Overactive Bladder Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2020–2027”. Overactive Bladder Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy